Online inquiry

IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7937MR)

This product GTTS-WQ7937MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ICOS gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_012092.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29851
UniProt ID Q9Y6W8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7937MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12899MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ5098MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ8641MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ1232MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ2574MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ14630MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ10434MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ13816MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW